Symbols

GKOS

Glaukos·NYSE

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Strong Buy"

MACD Death Cross

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GKOS

Glaukos Corporation

An ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases

Industry

Healthcare Equipment and Supplies

Established Date

07/14/1998

Listing Date

06/25/2015

Exchange

New York Stock Exchange

Full-time Employees

995

Fiscal Year Ends

12-31

Website

www.glaukos.com

Security Type

Common stock

Office address

One Glaukos Way, Aliso Viejo, California 92656

Business

Introduction

Glaukos Corporation was incorporated in Delaware on July 14, 1998. The company is an ophthalmic pharmaceutical and medical technology company focused on developing new drop-free therapies and commercializing related products for the treatment of glaucoma, corneal diseases and retinal diseases. They first developed minimally invasive glaucoma surgery (MIGS) as an alternative to the traditional glaucoma treatment model and launched their first MIGS device in 2012. They also offer a commercialized proprietary bioactivating drug therapy for the treatment of the rare corneal disease keratoconus, which was approved by the U.S. Food and Drug Administration (FDA) in 2016. They are developing a range of platforms to support ongoing pharmaceutical and medical device innovations.

Earnings Call

Q1/2025

Estimate EPS-0.35

Actual EPS-0.22

Estimate Revenue102.78M

Actual Revenue106.70M

Glaukos Q1 2025: Unraveling Contradictions in iDose Growth, Revenue, and Market Access

May 18,2025 09:40·
Earnings Decrypt

Q2/2025

Estimate EPS-0.26

Actual EPS-0.24

Estimate Revenue115.48M

Actual Revenue124.01M

Glaukos Corp's Q2 2025: Unraveling Key Contradictions in iDose Reimbursement, Reimplantation Timelines, and Growth Expectations

Jul 31,2025 06:26·
Earnings Decrypt

Company Financials

EPS

GKOS has released its 2025 Q3 earnings. EPS was reported at -0.16, versus the expected -0.26, beating expectations. The chart below visualizes how GKOS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GKOS has released its 2025 Q3 earnings report, with revenue of 133.54M, reflecting a YoY change of 38.14%, and net profit of -16.23M, showing a YoY change of 24.19%. The Sankey diagram below clearly presents GKOS's revenue sources and cost distribution.